Table 1.
Demographics & Baseline Characteristics
| Characteristic | Model 1* (N=698) |
Model 2t (N=2092) |
Model 3p (N=1929) |
Model 4** (N=996) |
|
|---|---|---|---|---|---|
| Age at Baseline (pre-ART) | < 20 | 5 (1%) | 13 (1%) | 10 (1%) | 11 (1%) |
| 20–29 | 125 (18%) | 373 (18%) | 340 (18%) | 207 (21%) | |
| 30–39 | 293 (42%) | 787 (38%) | 720 (37%) | 388 (39%) | |
| 40–49 | 198 (28%) | 653 (31%) | 609 (32%) | 280 (28%) | |
| 50–59 | 67 (10%) | 227 (11%) | 212 (11%) | 97 (10%) | |
| Over 60 | 10 (1%) | 39 (2%) | 38 (2%) | 13 (1%) | |
| Sex | Male | 598 (86%) | 1,713 (82%) | 1,579 (82%) | 832 (84%) |
| Female | 100 (14%) | 379 (18%) | 350 (18%) | 164 (16%) | |
| Race/Ethnicity | White | 321 (46%) | 899 (43%) | 852 (44%) | 482 (48%) |
| Black | 207 (30%) | 685 (33%) | 602 (31%) | 273 (27%) | |
| Hispanic | 150 (21%) | 443 (21%) | 412 (21%) | 206 (21%) | |
| Asian | 11 (2%) | 40 (2%) | 38 (2%) | 24 (2%) | |
| Native Indian/Alaskan | 4 (1%) | 9 (0%) | 9 (0%) | 3 (0%) | |
| Other | 5 (1%) | 11 (1%) | 11 (1%) | 6 (1%) | |
| Unknown/missing | 0 (0%) | 5 (0%) | 5 (0%) | 2 (0%) | |
| IV drug history | No | 637 (91%) | 1,905 (91%) | 1,757 (91%) | 904 (91%) |
| Yes | 61 (9%) | 187 (9%) | 172 (9%) | 92 (9%) | |
| HCV seropositivity | Positive ever | 79 (11%) | 209 (10%) | 190 (10%) | 89 (9%) |
| Negative | 597 (86%) | 1,883 (90%) | 1,739 (90%) | 896 (90%) | |
| Not available | 22 (3%) | 0 (0%) | 0 (0%) | 11 (1%) | |
| Baseline (pre-ART) CD4 Count (cells/ul) | N | 698 | 2,092 | 1,929 | 996 |
| Median | 238 | 226 | 229 | 350 | |
| Q1, Q3 | 109, 362 | 89, 335 | 94, 335 | 299, 440 | |
| Baseline (pre-ART) Log10(HIV RNA Viral Load),(cp/ml) | N | 698 | 2,092 | 1,929 | 996 |
| Median | 4.70 | 4.68 | 4.68 | 4.52 | |
| Q1, Q3 | 4.34, 5.20 | 4.36, 5.15 | 4.36, 5.13 | 4.15, 4.80 |
*
Model 1: Multivariable logistic regression model used to estimate association between pre-ART CD4 (full range) and neuropathy outcome
t
Model 2: Multivariable logistic GEE model used to estimate association between pre-ART CD4 (full range) and neuropathy outcome
p
Model 3: Same as Model 2 but restricted to sub-population (HIV-RNA VL ≤50cp/ml)
**
Model 4: ART-naïve subjects with pre-ART CD4 > 250 cells/µL